Patrick Wilton, MD, PhD
When the post marketing surveillance data base KIGS was initiated 1987 he was the clinical lead. The work with KIGS gave him numerous opportunities to present data at international meetings. He built a big network in the pediatric endocrinology field. He became medical director of KIGS and the second post surveillance database including data from adults with growth hormone deficiencies, KIMS, 2000. This increased his network to include also endocrinologists.Patrick Wilton graduated from Karolinska Institute and worked as a pediatrician in Stockholm for 15 years. Spent one year as a Clinical Fellow in Neonatology at Vanderbilt University, Nashville,TN,USA. His dissertation for PhD covered compensatory renal hypertrophy, 1979. He joined the Swedish pharmaceutical company KabiVitrum 1985 and became in charge of the clinical trials of the newly developed recombinant human growth hormone, Genotropin. He later was involved in clinical trials of IGF-I in growth hormone receptor deficient children (Laron syndrome). When Pfizer Inc acquired Pharmacia he was offered to lead Medical Outcomes from Pfizer’s headquarters in New York, USA. During all the years in the pharmaceutical industry he has continued to present Posters and give oral presentations. He is a member of European Society Pediatric Endocrinology, Endocrine Society.
